Compounded GLP-1 rules in 2026: the FDA 503B proposal, the warning letters, and what it means for you

If you have been following the news around compounded GLP-1 medications, you have probably seen headlines swinging between 'compounded semaglutide is banned' and 'compounded tirzepatide is still available.' It is genuinely confusing, and the confusion is not your fault. The regulatory situation has moved fast, and most coverage has been written for policy insiders rather than patients. This post gives you a straightforward account of where things actually stand in mid-2026, what the rules mean for you, and how StaveMD operates within them.

Why compounded GLP-1 medications exist in the first place

Compounded medications are not a loophole or a gray market. They are a legal, long-standing part of the US pharmaceutical system. Under federal law — specifically Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act — state-licensed compounding pharmacies and FDA-registered outsourcing facilities can prepare medications for patients when specific conditions are met. One of those conditions is FDA-documented shortage status for a given drug.

Tirzepatide, which is sold as the FDA-approved brand-name products Zepbound (for weight management) and Mounjaro (for type 2 diabetes), was placed on the FDA drug shortage list because demand dramatically outpaced supply after the clinical-trial data became public. SURMOUNT-1 showed a mean body-weight loss of up to approximately 20.9 percent at the 15 mg dose over 72 weeks — not StaveMD patient data, but trial data from Jastreboff et al., published in the New England Journal of Medicine in 2022. That kind of result drove enormous demand. Shortages followed. Compounding pharmacies were legally permitted to compound tirzepatide to help fill the gap.

Compounded tirzepatide is not an FDA-approved finished drug product. It is prepared by a US-licensed compounding pharmacy under a valid prescription from a licensed provider. That distinction matters legally and practically, and any honest telehealth company should make it clearly.

What changed in 2025 and 2026 — and what it means for compounded tirzepatide

In late 2024 and into 2025, the FDA concluded that the tirzepatide and semaglutide shortages had been resolved, which started a wind-down period for compounding that had relied on shortage status. Pharmacy groups challenged that decision in court, and compounding continued in a narrower form: patient-specific prescriptions where a provider documents an individual clinical need.

The April 2026 503B proposal

On April 30, 2026, the FDA proposed to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list, the list that lets FDA-registered outsourcing facilities compound a drug from bulk ingredients in large batches. The agency's position is that there is no clinical need for outsourcing facilities to compound these drugs from bulk while FDA-approved versions are available. The comment period was extended to July 30, 2026, and as of this update a final decision has not been announced.

The proposal is about 503B outsourcing facilities. It does not address 503A pharmacies, which prepare medication for one named patient under one prescription. That is the route most individual compounded prescriptions take, and it is the route StaveMD's partner pharmacies use. If the proposal is finalized, expect some programs that relied on 503B batch supply to change what they offer, sometimes with little notice to patients.

• 503B (outsourcing facilities, batch production): the April 2026 proposal would end bulk compounding of tirzepatide and semaglutide here
• 503A (state-licensed pharmacies, patient-specific prescriptions): not the subject of the proposal; still requires a documented individual clinical need
• FDA-approved brand-name products: unaffected by the proposal
• Status as of September 24, 2026: proposal pending, no final determination announced

The 2026 warning letters to telehealth companies

The FDA has also been policing how compounded GLP-1s are marketed. On March 3, 2026, it announced warning letters to 30 telehealth companies, and in June 2026 it posted letters to 25 more. The problems it named were consistent: marketing that presented a compounded product as interchangeable with an FDA-approved drug, and branding that put the telehealth company's name on a compounded product without making clear who actually compounded it. In the FDA's words, compounded drugs are not FDA-approved, and they are also not the same as generic drugs, which are FDA-approved.

For a patient, the letters are a useful checklist. A provider that tells you its compounded medication is the same drug as a brand, or implies FDA approval, is making the exact claim the FDA has been writing letters about. That is worth knowing before you pay.

What this means practically: access to compounded tirzepatide through telehealth providers like StaveMD depends on the current regulatory status, which can change. If you have seen other companies quietly stop offering compounded tirzepatide or raise prices without explanation, that is almost certainly a regulatory response rather than a simple business decision. Transparency here matters, and you deserve a straight answer rather than vague reassurances.

How to tell if a telehealth company is operating honestly

You mentioned being burned before. That is one of the most common things we hear. Here are the specific things worth checking before you hand over a credit card to any GLP-1 telehealth company:

• Does the company clearly state that compounded tirzepatide is not FDA-approved? If they imply otherwise, that is a red flag.
• Do they disclose which pharmacy prepares the medication, or at minimum confirm it is a US-licensed facility? Vagueness here is a warning sign.
• Is the pricing shown upfront, including what happens after the first month? Bait-and-switch pricing — a low introductory rate followed by a sharp increase — is common in this space.
• Does the company distinguish between the tirzepatide molecule's clinical-trial data (from studies like SURMOUNT-1 and SURMOUNT-5) and their own patient outcomes? Any company showing SURMOUNT results as their own results is misrepresenting the evidence.
• Is there a real licensed provider reviewing your intake, or is approval essentially automatic? Automatic approvals are a compliance problem, not a convenience.
• What is the process if you experience side effects? Nausea, vomiting, and gastrointestinal discomfort are common, particularly during dose escalation. A legitimate provider should have a protocol for managing this.

The biology behind why this medication works — and why your history of failed diets is not a character flaw

Tirzepatide is a dual agonist: it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. These are hormonal pathways that regulate appetite, gastric emptying, and how your brain processes food-reward signals. One of the effects most patients notice first is a significant reduction in what is often called 'food noise' — the constant background mental chatter about eating, craving, and restriction that many people have lived with for years.

If that chatter has been loud for you, it is worth knowing that research supports a biological explanation. The NIH-funded study of Biggest Loser contestants (Fothergill et al., Obesity, 2016) documented that sustained calorie restriction produces measurable metabolic adaptation — the body reduces its resting metabolic rate in ways that persist long after the diet ends. This is not a matter of discipline. It is a physiological response that makes regain nearly inevitable through diet alone for many people. GLP-1 receptor agonists work on different mechanisms — hormonal signaling rather than willpower — which is part of why their clinical results have been meaningfully different from behavioral interventions alone.

To be honest about what the evidence shows: SURMOUNT-1 trial data (not StaveMD patient data) reported mean weight loss of approximately 20.9 percent at 15 mg tirzepatide over 72 weeks. The SURMOUNT-5 trial compared tirzepatide directly to semaglutide and found greater average weight loss with tirzepatide (-20.2 percent versus -13.7 percent). These are averages from randomized controlled trials. Individual results vary. Some people lose considerably less; some lose more. Side effects are real, particularly early in treatment. None of this should be glossed over.

What StaveMD does — and does not — promise

StaveMD connects patients with licensed providers who can evaluate whether compounded tirzepatide is clinically appropriate and, where it is, write a valid prescription. The compounding pharmacy prepares and ships the medication directly to you. StaveMD does not manufacture or compound the medication. The efficacy data cited on this site comes from published clinical trials of the tirzepatide molecule — not StaveMD patient data — because we have not run our own randomized trial and we are not going to pretend otherwise.

Pricing is listed clearly. If the regulatory landscape changes in a way that affects availability or cost, we will communicate that directly rather than quietly raising prices or sending a confusing cancellation email. You have been through enough programs that over-promised. That is not what this is.